Compare Dicks Sporting Goods Inc (DKS) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Davita Inc — how do they compare? Dicks Sporting Goods Inc trades at $135.15 (market cap $12.92B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Dicks Sporting Goods Inc and Davita Inc are close in size by market cap, and Dicks Sporting Goods Inc pays a 3.81% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Davita Inc for 113 Days on average.
| DKS | DVA | |
|---|---|---|
Market Cap | $12.92B | $11.28B |
Volume | 2,077,432 | 650,294 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $240.96 |
52-Week Low | $121.15 | $103.87 |
Typical Hold Time | 19 Days | 113 Days |
Enterprise Value | $19.97B | $24.00B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, with a bearish technical signal from moving averages and oscillators. The company shows solid profitability with an 18.47% ROE and a net income margin of 3.97%, though recent earnings missed expectations in Q2 2026. Revenue grew to $13.44B in 2025, but profit margins are projected to compress in 2026. A securities class action lawsuit filed for the period September 2025 to August 2026 adds legal overhang.
The stock presents a mixed outlook; strong analyst consensus with a $153.30 price target suggests 17% upside, supported by a reasonable P/E of 14.48. However, near-term risks include the class action litigation, technical bearishness, and margin pressure. The dividend increase to $1.25 signals confidence, but investors must weigh legal and operational headwinds against valuation appeal.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
